Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: Identification of 5-methyl-1-[[2-[(2-methyl-3- pyridyl)oxy]5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent

Journal of Medicinal Chemistry

Volumn 43, Issue 6, 2000, Pages 1123-1134

  Bromidge, Steven M ^a,b   Dabbs, Steven ^a,b   Davies, David T ^a,b   Davies, Susannah ^a,b   Duckworth, D Malcolm ^a,b   Forbes, Ian T ^a,b   Gaster, Laramie M ^a,b   Ham, Peter ^a,b   Jones, Graham E ^a,b   King, Frank D ^a,b   Mulholland, Keith R ^a,b   Saunders, Damian V ^a,b   Wyman, Paul A ^a,b   Blaney, Frank E ^a,b   Clarke, Stephen E ^a,c   Blackburn, Thomas P ^a,c   Holland, Vicky ^a,c   Kennett, Guy A ^a,c   Lightowler, Sean ^a,c   Middlemiss, Derek N ^a,c   Trail, Brenda ^a,c   Riley, Graham J ^a,c   Wood, Martyn D ^a,c   more..

^a GLAXOSMITHKLINE   (United Kingdom)

^b Discovery Chemistry Europe   (United Kingdom)

^c Department of Neurosciences Research ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL] 6 TRIFLUOROMETHYLINDOLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BIARYLCARBAMOYLINDOLINE; INDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANXIETY NEUROSIS; ARTICLE; CHOROID PLEXUS; COMPETITIVE INHIBITION; DEPRESSION; DRUG SYNTHESIS; MOLECULAR RECOGNITION; PROTEIN DOMAIN; RECEPTOR BINDING; SECOND MESSENGER;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; CELL LINE; HUMANS; INDOLES; MODELS, MOLECULAR; MOTOR ACTIVITY; PYRIDINES; RADIOLIGAND ASSAY; RATS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034704836     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990388c     Document Type: Article

References (42)

1. Hoyer, D.; Clarke, D. E.; Fozard, J. R.; Hartig, P. R.; Martin, G. R.; Mylecharane, E. J.; Saxena, P. R.; Humphrey, P. P. A. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine. Pharmacol. Rev. 1994, 46, 157-203.
2. (a) Humphrey, P. P. A.; Hartig, P.; Hoyer, D. A Proposed New Nomenclature of 5-HT Receptors. Trends Pharmacol. Sci. 1993, 14, 233-236.
3. 2 Subfamily of Receptors: Pharmacological Challenges. Med. Chem. Res. 1993, 3, 306-316.
4. 2 Receptor Subtypes: A Family Re-united? Trends Pharmacol. Sci. 1995, 16, 105-110.
5. (a) Kahn, R. S.; Wetzler, S. mCPP as a Probe of Serotonin Function. Biol. Psychiat. 1991, 30, 1139-1166.
6. 1C Receptor Antagonists have Anxiolytic-like Actions in the Rat Social Interaction Model. Psychopharmacology 1992, 107, 379.
7. 1C receptors and their therapeutic relevance. Curr. Opin. Invest. Drugs 1993, 2, 317-362 and references therein.
8. 1C Receptor Antagonists are Anxiolytic in the Geller-Seifter Model of Anxiety. Psychopharmacology 1994, 114, 90-96.
9. 2C/2B Receptor Antagonist. Br. J. Pharmacol. 1994, 111, 797-802.
10. 2B receptor antagonist with anxiolytic-like properties. Br. J. Pharmacol. 1996, 117, 427-434.
11. 2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modelling of substituted 1-(3-pyridylcarbamoyl)indolines. J. Med. Chem. 1998, 41, 1598-1612.
12. 2C Receptor Antagonist. Neuropharmacology 1997, 36, 609-620.
13. (a) Kennett, G. A.; Lightowler, S.; De Biasi, V.; Stevens, N. C.; Wood, M. D.; Tulloch, I. F.; Blackburn, T. P. Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function. Neuropharmacology 1994, 33, 1581-1588.
14. (b) Palvimaki, E. P.; Roth, B. L.; Majasuo, H.; Laakso, A.; Kuoppamaki, M.; Syvalahti, E.; Hietala, J. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2C receptor. Psychopharmacology 1996, 126, 234-240.
15. 2C serotonin receptors by fluoxetine (Prozac). Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 2036-2040.
16. (d) Quested, D. J.; Sargent, P. A.; Cowen, P. J. SSRI treatment decreases prolactin and hyperthermic responses to mCPP. Psychopharmacology 1997, 133, 305-308.
17. 2C agonists mimic the effect of light pulses on circadian rhythms. Brain Res. 1998, 806, 257-270.
18. 2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression. Eur. Neuropsychopharmacol. 1996, 6, 169-175.
19. (a) Di Giovanni, G.; De Deurwaerdere, P.; Di Mascio, M.; Di Matteo, V.; Esposito, E.; Spampinato, U. Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: A combined in vivo electrophysiological and microdialysis study. Neuroscience 1999, 91, 587-597.
20. (b) Dimatteo, V.; Digiovanni, G.; Dimascio, M.; Esposito, E. Selective blockade of serotonin(2C/2B) receptors enhances dopamine release in the rat nucleus accumbens. Neuropharmacology 1998, 37, 265-272.
21. 2C receptors tonically inhibit dopamine and noradrenaline, but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 1998, 37, 953-955.
22. 2C receptor antagonist. Br. J. Pharmacol. 1999, 126, 572-574.
23. 2C receptor blockade. Life Sci. 1994, 54, 641-644.
24. 2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 1998, 151, 35-49.
25. 2C Receptor Antagonist. J. Med. Chem. 1997, 40, 3494-3496.
26. 2C/2B Receptor Antagonists. J. Med. Chem. 1996, 39, 4966-4977.
27. Gaster, L. M.; Wyman, P. A.; Mulholland, K. R.; Davies, D. T.; Duckworth, D. M.; Forbes, I. T.; Jones, G. E. WO Patent 96/23,783, Aug 8, 1996.
28. Stanforth, S. P. Catalytic cross-coupling reactions in biaryl synthesis. Tetrahedron 1998, 54, 263-303.
29. Kuznetsova, E. A.; Voronina, T. A.; Khromova, I. V.; Garibova, T. L.; Tosina, E. K.; Stolyarova, L. G.;Troitskaya, V. S.; Smirnov, L. D. Amino acid derivatives of nicotinic acids: synthesis and pharmacological activity. Khim.-Farm. Zh. 1989, 23, 1425-1431.
30. Farina, V.; Krishnamurthy, V.; Scott, W. J. The Stille reaction. Org. React. 1997, 50, 1-652.
31. Bromidge, S. M.; Forbes, I. T. WO Patent 97/48,699, Oct 16,1997.
32. Echavarren, A. M.; Stille, J. K. Palladium Coupling of Aryl Triflates with Organostannanes. J. Am. Chem. Soc. 1987, 109, 5478-86.
33. Friedman, H. L.; Braitberg, L. D.; Tolstoouhov, A. V.; Tisza, E. T. Tuberculostatic compounds. I. Ethers of 2-hydroxy-5-aminopyridine. J. Am. Chem. Soc. 1947, 69, 1204-1206.
34. Baldwin, S. J.; Bloomer, J. C.; Smith, G. J.; Ayrton, A. D.; Clarke, S. E.; Chenery, R. J. Ketoconazole and Sulfaphenazole as the respective selective inhibitors of P450 3A and 2C9. Xenobiotica 1995, 25, 261-270.
35. 2C Receptor Mutant Mice. Am. Soc. Neurosci. 1996, 22 (Abstr), 811.2.
36. 2C serotonin receptors. Nature 1995, 374, 542-546.
37. Unpublished results from the Department of Drug Metabolism and Pharmacokinetics, SmithKline Beecham.
38. 2C receptor systems. Mol. Pharmacol. 1999, 55, 863-872.
39. 2C receptors in affective disorders. Exp. Opin. Invest. Drugs 1998, 7, 1587-1599.
40. Detailed in vivo biological results will be published elsewhere.
41. Mangutova, Y. S.; Mal'tseva, L. S.; Kamaev, F. G.; Leont'ev, V. B.; Mukhamedkhanova, S.; Otroshchenko, O. S.; Sadykov, A. S. Stereochemistry and electronic structure in a series of dipyridyls. Izv. Akad. Nauk SSSR, Ser. Khim. 1973, 7, 1510-1517.
42. Suzuki, F.; Nakasato, Y.; Tumuki, H.; Sato, S.; Tamura, T.; Nakajima, H. Preparation of novel tetracyclic condensed quinoline derivatives as immunosuppressants. WO Patent 95/09,153, Apr 6, 1995.